{
  "protocol_version": "evo-1.0",
  "session_id": "evo_20260212_032819_pharmacology",
  "timestamp": "2026-02-12T03:30:39.454228+00:00",
  "question": "What determines whether VDAC1 engagement by a small molecule results in neuroprotection versus cytotoxicity? Specifically, how do cell-type-specific cofactor landscapes \u2014 including HK-II occupancy, Bcl-2 family association, and tubulin binding \u2014 set the threshold at which VDAC1 transitions from metabolic gating to oligomerization-mediated apoptosis?",
  "outcome": "S3_FAILED",
  "cycles": 3,
  "total_calls": 15,
  "convergence_report": {
    "stage": "S3",
    "passed": false,
    "convergence_score": 0.3401,
    "convergence_threshold": 0.85,
    "convergence_pass": false,
    "jaccard": 0.217,
    "jaccard_threshold": 0.85,
    "jaccard_pass": false,
    "type_01_ratio": 0.2727,
    "type_01_threshold": 0.75,
    "type_pass": false,
    "cosine": 0.3401,
    "jsd": 0.1333,
    "kappa": 0.97,
    "type_distribution": {
      "0": 0.0,
      "1": 0.2727272727272727,
      "2": 0.36363636363636365,
      "3": 0.36363636363636365
    },
    "divergence_map": {
      "total_unique_claims": 12,
      "most_divergent": [
        {
          "statement": "1:** The neuroprotection-to-cytotoxicity transition follows a cooperative oligomerization threshold: apoptosis requires \u22654 adjacent cofactor-free VDAC1 monomers, so cytotoxicity probability scales as (f_free)^4, where f_free = fraction of VDAC1 not bound by HK-II, Bcl-xL, or tubulin.",
          "models_supporting": [
            "claude"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.7
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "2:** In neurons (HK-II occupancy ~50-60%, Bcl-xL/Bax >5, free tubulin ~20 \u00b5M), the effective cytotoxic threshold is >55 \u00b5M CBD (~5\u00d7 Kd), yielding TI >10. In glioblastoma (HK-II occupancy ~15%, Bcl-xL/Bax ~1, low free tubulin), the threshold is ~15-20 \u00b5M, yielding TI ~3-5.",
          "models_supporting": [
            "claude"
          ],
          "types_assigned": [
            3
          ],
          "confidences": [
            0.5
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "3:** The biphasic response is mechanistically distinct at low vs. high occupancy: sub-Kd CBD (<5 \u00b5M) allosterically enhances HK-II\u2013VDAC1 affinity (positive cooperativity at N-terminal helix), while supra-3\u00d7Kd CBD (>33 \u00b5M) induces N-terminal helix displacement, competitively ejecting HK-II.",
          "models_supporting": [
            "claude"
          ],
          "types_assigned": [
            3
          ],
          "confidences": [
            0.45
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "4:** Tubulin binding to VDAC1 C-terminus (Kd ~1-2 \u00b5M) provides a secondary steric block to oligomerization that is quantitatively significant only in cells with high free tubulin (neurons, not astrocytes), raising the threshold ~2-fold independently of HK-II.",
          "models_supporting": [
            "claude"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.55
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "The cytotoxic threshold for VDAC1 ligands scales as Kd \u00d7 (1 + [HK-II]/Ki_HK) \u00d7 (Bcl-xL/Bax) \u00d7 (1 + [tubulin]/Ki_tub), yielding >10\u00d7 higher thresholds in neurons (TI > 10) vs. cancer cells (TI < 5).",
          "models_supporting": [
            "mistral"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.75
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "CBD\u2019s biphasic effect arises from allosteric modulation at sub-Kd (<5 \u00b5M) vs. competitive displacement at supra-Kd (>20 \u00b5M), with the inflection point determined by HK-II occupancy.",
          "models_supporting": [
            "mistral"
          ],
          "types_assigned": [
            1
          ],
          "confidences": [
            0.8
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "Tubulin binding to VDAC1\u2019s C-terminus (Kd ~1 \u00b5M) raises the cytotoxic threshold 2\u00d7 by sterically blocking inter-VDAC1 contacts, but this effect is saturable and cell-type-dependent (high in neurons, low in astrocytes).",
          "models_supporting": [
            "mistral"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.7
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "The therapeutic index for VDAC1 ligands is cofactor-limited: neurons achieve TI > 10 due to high HK-II and Bcl-xL buffering, while astrocytes (low HK-II, high tubulin) have TI < 5 because tubulin\u2019s protective effect is weaker.",
          "models_supporting": [
            "mistral"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.65
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "Oligomerization requires \u22654 adjacent free VDAC1 monomers, so the cytotoxic probability scales as (fraction_free_VDAC1)^4, explaining the steep dose-response curve.",
          "models_supporting": [
            "mistral"
          ],
          "types_assigned": [
            1
          ],
          "confidences": [
            0.85
          ],
          "type_variance": 0,
          "n_supporters": 1
        },
        {
          "statement": "The biphasic dose-response is an emergent property of mass-action ligand binding, not a switch in mechanism. Low concentrations (< Kd) have minimal impact on the high-affinity VDAC1-cofactor equilibrium, allowing for subtle neuroprotective effects (e.g., channel stabilization), while high concentrations (>5x Kd) are required to competitively displace protective cofactors and expose VDAC1 for oligomerization.",
          "models_supporting": [
            "gemini"
          ],
          "types_assigned": [
            2
          ],
          "confidences": [
            0.85
          ],
          "type_variance": 0,
          "n_supporters": 1
        }
      ],
      "models_present": [
        "claude",
        "mistral",
        "grok",
        "gemini",
        "deepseek"
      ]
    },
    "recommendation": "S3 gate FAILED. The system did not converge to stable consensus. This indicates genuine scientific disagreement worth investigating. Review the divergence map below."
  }
}